China Development Research Foundation   |   中文   |   Register
Time:March 18-20, 2017
Beijing Diaoyutai State Guesthouse
Sponsor:Development Research Center of the State Council
Organiser:China Development Research Foundation
CDF WeChat
CDRF WeChat
CDRF Weibo
Q&A
Chinese Delegates International Delegates Participating Organisations

Back International Delegates List>

John Young

Group President, Pfizer Essential Health Business Circle

Through a broad portfolio of more than 600 products, global reach in 160-plus markets, and a reputation for trust and quality, the Pfizer Essential Health business aims to meaningfully contribute to improving global health by making Pfizer’s quality medicines accessible to patients around the world.


Pfizer Essential Health is a leader in non-viral anti-infectives, biosimilars, and off-patent sterile injectables. In emerging markets, its portfolio of affordable, well-known branded medicines, innovative delivery mechanisms, and high-quality manufacturing make it a key partner in the global health space. Pfizer Essential Health is set to grow through innovation in its core product categories through a dedicated R&D organization, combined with a focus on “open science” to acquire new molecules developed outside of Pfizer, while retaining a steadfast focus on the patients and customers we serve.


John has more than 25 years’ experience with Pfizer and has held a number of senior global positions across the organization. A scientist by training, he began his Pfizer career in the UK as a trainee Sales Representative and held various positions in sales and marketing before taking the role of Australia Country Manager, and later UK Country Manager. Following these experiences, he assumed the role of Regional President, Europe, Canada, Australia, and New Zealand for the Primary Care Business Unit. He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes, and pain.


John is a member of the Boards of EFPIA (European Federation of Pharmaceutical Industry Associations), the NCUSCR (National Committee for US China Relations), and has been a member of the UK Government bioscience working group, the MISG (Ministerial Industry Strategy Group), since 2008.


John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School. He is married with three daughters.